By Doug Macron

With an antisense-based drug already in a small phase I study, Bio-Path Holdings has begun eyeing the RNAi space with the hope that the ongoing clinical trial will confirm the efficacy of its proprietary delivery technology and help it secure capital to advance an siRNA therapeutic into the clinic.

Bio-Path was founded in 2007 to commercialize a drug-delivery approach developed at MD Anderson Cancer Center that involves the use of neutral lipids to carry oligonucleotide payloads.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

An Australian study of personalized medicine has run into problems as it recruits patients.